Live Breaking News & Updates on Ophthalmic Genetics

Stay updated with breaking news from Ophthalmic genetics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Renowned Pioneers in Ophthalmology Join SparingVision's Scientific Advisory Board


Renowned Pioneers in Ophthalmology Join SparingVision s Scientific Advisory Board
Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
Paris, January 29, 2021 - SparingVision (the Company ), a genomic medicine company developing vision saving treatments for ocular diseases, today announces the strengthening of its Scientific Advisory Board ( SAB ) with the appointment of internationally renowned ophthalmology pioneers Dr. Paul A. Sieving, Professor of University of California Davis School of Medicine and the former Director of the US National Eye Institute, and Prof. Botond Roska, co-director of the Institute of Molecular and Clinical Ophthalmology Basel and Professor at the Medical and Science Faculty of the University of Basel. ....

United States , Israel General , France General , Hebrew University , University Of California Davis , Olivia Manser , Jacque Duncan , Pierre Chambon , Arne Holmgren , Botond Roska , Eyal Banin , Bart Leroy , Masayo Takahashi , Tjean Bennett , Karolinska Institutet , Jean Bennet , Amber Fennell , Lizzie Seeley , Kostenloser Wertpapierhandel , Paulr Lichter , Elias Arn , Nathalie Trepo , Centre For Retinal , Head Of Department Ophthalmology , Department Of Medical Biochemistry , Hadassah Medical Centre ,

Clinical update - Treatment of first patient cohort completed in Phase 2a extension of retinal disease study


Search jobs
15-Jan-2021
Treatment of first patient cohort completed in Phase 2a extension of retinal disease study
 
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update on progress with the development of its hRPC (human retinal progenitor cell) therapy candidate for retinal diseases.
 
The hRPC therapeutic candidate is currently undergoing Phase 2a clinical evaluation for the treatment of the inherited blindness-causing disorder retinitis pigmentosa (RP).  The study uses a cryopreserved hRPC formulation, enrols subjects with advanced RP with some remaining central vision and, thus far, has been conducted at two clinical sites in the US. ....

United States , United Kingdom , Mark Pennesi , Kennethc Swan , Reneuron Group , Paulh Casey Ophthalmic Genetics Division , Casey Eye Institute , Oregon Health Science University , Neuron Group , United Kingdom Based , Data Safety Monitoring Board , Oregon Health , Principal Investigator , Associate Professor , Endowed Professor , Ophthalmic Genetics , Orphan Drug Designation , Fast Track , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , வழக்கு கண் நிறுவனம் , ஓரிகந் ஆரோக்கியம் அறிவியல் பல்கலைக்கழகம் , நரம்பியல் குழு , ஒன்றுபட்டது கிஂக்டம் அடிப்படையிலானது , தகவல்கள் பாதுகாப்பு கண்காணிப்பு பலகை , ஓரிகந் ஆரோக்கியம் ,